Safron Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 22-06-2024
- Paid Up Capital ₹ 0.10 M
as on 22-06-2024
- Company Age 14 Year, 17 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 M
as on 22-06-2024
- Revenue 16.66%
(FY 2022)
- Profit 112.24%
(FY 2022)
- Ebitda -38.85%
(FY 2022)
- Net Worth 1.89%
(FY 2022)
- Total Assets -8.08%
(FY 2022)
About Safron Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.00 M.
Mukesh Gupta, Rohit Singhal, Sanju Vijay, and Two other members serve as directors at the Company.
- CIN/LLPIN
U85100MH2010PTC210796
- Company No.
210796
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Dec 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Safron Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohit Singhal  | Director | 06-Jan-2014 | Current |
| Mukesh Gupta | Director | 07-Aug-2015 | Current |
| Sanju Vijay | Director | 08-Dec-2010 | Current |
| Mahesh Gupta | Director | 08-Dec-2010 | Current |
| Manish Mittal | Director | 18-Jul-2013 | Current |
Financial Performance of Safron Pharmaceuticals.
Safron Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 16.66% increase. The company also saw a substantial improvement in profitability, with a 112.24% increase in profit. The company's net worth moved up by a moderate rise of 1.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Safron Pharmaceuticals?
In 2021, Safron Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Health First Pharmacy Private LimitedActive 10 years 22 daysRohit Singhal and Mahesh Gupta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Oct 2017 | ₹4.00 M | Open |
How Many Employees Work at Safron Pharmaceuticals?
Unlock and access historical data on people associated with Safron Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Safron Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Safron Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
